Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma [A19276]. It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where it methylates homocysteine and forms methionine and tetrahydrofolate (THF). Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773]. It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.
Levomefolate Calcium, Cyanocobalamin and Pyridoxine Hydrochloride
EnBrace HR
Quflora FE Pediatric Drops
EnLyte
Vitafol Nano
Niferex
Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium
Livita Children
Tricare Prenatal 2-part Daily Prenatal Vitamin System
L-Methyl MC
PreGenna
Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Levomefolate Calcium Acetylcysteine and Mecobalamin Algal
Folixate
Rajani
Quflora Pediatric
Multitol-M
Virt-PN DHA
Obstetrix ONE
Obstetrix DHA Combo Pack
OBTREX DHA Combo Pack
PNV Tabs 20-1
Prenate Mini
Sulfzix
Florravite
Tri-Vi-Flor
Medi-10
Levomefolate Calcium and Schizochytrium DHA
Davimet-M
Folene
Poly-Vi-Flor
Levomefolate Calcium, Acetylcysteine, Mecobalamin and Algal
Yasmin Plus
L-Methyl-MC-NAC
Yaz Plus
Prenate Essential
Prenatol-M
Poly-VI-flor
Multivitamin with Fluoride
NuFera
Maxaron Forte
Zatean-Pn DHA
Floriva
Biopar delta-FORTE
WellFola
Indication
For the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682